Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-23T20:17:52.842Z Has data issue: false hasContentIssue false
  • English
  • Français

The utility of neuroSPECT imaging in the investigation of dementia and parkinsonism

Published online by Cambridge University Press:  13 June 2014

David Wyper  and
James Patterson
James Patterson
Affiliation:
South Glasgow University Hospitals NHS Trust, 1345 Govan Road, Glasgow, G51 4TF, Scotland
Get access Rights & Permissions [Opens in a new window]

Abstract

Functional neuroimaging is playing an increasing role in psychiatry and has moved from academic isolation into clinical practice. This review examines the basis for the use of Single Photon Emission Computed Tomography, the most widely available functional modality, in the two important areas of dementia and parkinsonism. Its contribution to the diagnosis and management of patients is discussed and its likely impact in clinical trials indicated. As functional imaging moves closer to those most able to utilise its power its impact in these and other areas of psychiatry and neurology will increase further.

Keywords

DementiaParkinsonismSPECTAlzheimer's diseaseLewy body dementia.
Type
Review
Information
Irish Journal of Psychological Medicine , Volume 17 , Issue 3 , September 2000 , pp. 96 - 99
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Lowe, J. Establishing a pathological diagnosis in degenerative dementias. Brain Pathology 1998;8:403–6.CrossRefGoogle ScholarPubMed
2.Jackson, M, Lowe, J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathology (Berl) 1996;91:127–34.CrossRefGoogle ScholarPubMed
3.McKeith, IG, Galasko, D, Kosaka, Ket al.Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–24.CrossRefGoogle Scholar
4.Pasquier, F, Leys, D. Why are stroke patients prone to develop dementia? J Neurology 1997;244:135–42.CrossRefGoogle ScholarPubMed
5.Roman, GC, Tatemichi, TK, Erkinjuntti, T, Cummings, JL, Masdeu, JC, Garcia, JH, Amaducci, L, Orgogozo, JM, Brun, A, Hofman, A. X. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–60.CrossRefGoogle ScholarPubMed
6.Heyman, Aet al.Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII. Consortium to establish a registry for Alzheimer's Disease. Neurology 1998; 51: 159–62.CrossRefGoogle ScholarPubMed
7.American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association.Google Scholar
8.Varma, AR, Talbot, PR, Snowden, JS, Lloyd, JJ, Testa, HJ, Neary, D. A 99m Tc-HMPAO single-photon emission computed tomography srudy of Lewy body disease. J Neurology 1997;244:349–59.CrossRefGoogle Scholar
9.Pametti, L, Lowenthal, DT, Presciutti, O, Pelliccioli, GP, Palumbo, R, Gobbi, G, Chiarini, P, Palumbo, B, Tarducci, R, Senin, U. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. Journal American Geriatric Society 1996;44:133–8.Google Scholar
10.Dolan, RJ, Bench, CJ, Brown, RG, Scott, LC, Friston, KJ, Frackowiak, RS. Regional cerebral blood flow abnormalities in depressed patients with cognitive impairment. J Neurology, Neurosurgery and Psychiatry 1992;55:768–73.CrossRefGoogle ScholarPubMed
11.Holman, BL, Johnson, KA, Gerada, B, Carvalho, PA, Satlin, A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nuclear Medicine 1992;33:181–5.Google ScholarPubMed
12.Pasquier, F, Lavenu, I, Lebert, F, Jacob, B, Steinling, M, Petit, H. The use of SPECT in a multidisciplinary memory clinic. Dementia Geriatric Cognitive Disorders 1997;8:85–91.CrossRefGoogle Scholar
13.Ibanez, V, Pietrini, P, Alexander, GE, Furey, ML, Teichberg, D, Rajapakse, JC, Rapoport, SI, Schapiro, MB, Horwirz, B. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998; 50: 1585–93.CrossRefGoogle Scholar
14.Worsley, DF, Alavi, A. Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J Nuclear Medicine 1995;36:2380–7.Google ScholarPubMed
15.Jobst, KA, Barnetson, LP, Shepstone, BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-rayCT, and ApoE4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. International Psychogeriarrica 1998;10:271–302.Google Scholar
16.Nagy, Z, Esiri, MM, Hindley, NJ, Joachim, C, Morris, JH, King, EM, McDonald, B, Litchfield, S, Barnetson, L, Jobst, KA, Smith, AD. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dementia Geriatric Cognitive Disorders 1998;9:219–26.CrossRefGoogle ScholarPubMed
17.Varma, AR, Snowden, JS, Lloyd, JJ, Talbot, PR, Mann, DM, Neary, D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. Journal Neurology, Neurosurgery and Psychiatry 1999;66:184–8.CrossRefGoogle ScholarPubMed
18.Bonte, FJ, Weiner, MF, Bigio, EH, White, CL. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997;202:793–7.CrossRefGoogle ScholarPubMed
19.Lim, A, Tsuang, D, Kukull, W, Nochlin, D, Leverenz, J, McCormick, W, Bowen, J, Teri, L, Thompson, J, Peskind, ER, Raskind, M, Larson, EB. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. Journal American Geriatric Society 1999;47:564–9.CrossRefGoogle Scholar
20.Lassen, NA. A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: the advantage of a longer half-life! Eur J Nucl Med. 1996 Jan; 23(1): 1–4.CrossRefGoogle ScholarPubMed
21.Kelly, RC, Hunter, R. Current Pharmacological strategies in Alzheimer's Disease. International Journal Geriatric Psychiatry 1995;10:633–46.CrossRefGoogle Scholar
22.Rogers, SL, Friedhoff, LT. The Donepezil Study Group. Dementia. 1996; 7(6): 293–303.Google ScholarPubMed
23.Kuhl, DE, Minoshima, S, Fessler, JA, Frey, KA, Foster, NL, Ficaro, EP, Wieland, DM, Koeppe, RA. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996 Sep; 40(3): 399–410.CrossRefGoogle ScholarPubMed
24.Wyper, DJ, Brown, D, Patterson, J, Owens, J, Hunter, R, Teasdale, E, McCulloch, J. Deficits in iodine-labelled 3-quinuclidinyl benzilare binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur J Nucl Med. 1993; 20(5): 379–86.CrossRefGoogle ScholarPubMed
25.Rajput, AH, Rozdilsky, B, Rajput, A. Accuracy of clinical diagnosis in parkinsonism — a prospective study. Can J Neuro Sci 1991;18:275–8.CrossRefGoogle ScholarPubMed
26.Hughes, AJ, Daniel, SE, Kilford, L, Lees, AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol, Neurosurg and Psychiatry 1992;55:181–4.CrossRefGoogle ScholarPubMed
27.Meara, J, Bhowmick, BK, Hobson, P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99–102.CrossRefGoogle ScholarPubMed
28.Asenbaum, S, Pirker, W, Angelberger, P, Bencsits, G, Pruckmayer, M, Brucke, T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105(10–12): 1213–1228.CrossRefGoogle Scholar
29.Benamer, TS, Patterson, J, Grosset, DG, Booij, J, de Bruin, K, van Royen, E. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15(3): 503–10.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
30.Seibyl, JP, Marek, KL, Quinlan, D, Sheff, K, Zoghbi, S, Zea-Ponce, Y. Decreased single-photon emission computed tomographic [123I]bera-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38(4): 589–98.CrossRefGoogle ScholarPubMed
31.Booij, J, Tissingh, G, Boer, GJ, Speelman, JD, Stoof, JC, Janssen, AG. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62(2): 133–40.CrossRefGoogle Scholar
32.Schwarz, J, Linke, R, Kerner, M, Mozley, PD, Trenkwalder, C, Gasser, T, Tatsch, K. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 2000; 57(2): 205–8.CrossRefGoogle ScholarPubMed
33.Brucke, T, Asenbaum, S, Pirker, W, Djamshidian, S, Wenger, S, Wober, C, Muller, C, Podreka, I. Measurement of the dopaminergic degeneration in Parkinson's disease with [1231] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24.Google ScholarPubMed
34.Kim, SE, Lee, WY, Choe, YS, Kim, JH. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res 1999; 21(3): 255–61.CrossRefGoogle ScholarPubMed
35.Knable, MB, Jones, DWCoppola, R, Hyde, TM, Lee, KS, Gorey, J, Weinberger, DR. Lateralized differences in iodine- 123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 1995; 36(7): 1216–25.Google Scholar
36.Wenning, GK, Donnemiller, E, Granata, R, Rtccabona, G, Poewe, W. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998; 13(3): 438–45.CrossRefGoogle ScholarPubMed
37.van Royen, E, Verhoeff, NF, Speelman, JDet al.Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993 May; 50(5): 513–6.CrossRefGoogle ScholarPubMed
38.Schulz, JB, Klockgether, T, Petersen, D, Jauch, M, Muller-Schauenburg, W, Spieker, S, Voigt, K, Dichgans, J. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57(9): 1047–56.CrossRefGoogle ScholarPubMed
39.Schwarz, J, Tatsch, K, Gasser, T, Arnold, G, Oertel, WH. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimeric therapy. Mov Disord 1997; 12(6): 898–902CrossRefGoogle Scholar
40.Schwarz, J, Tatsch, K, Gasser, T, Arnold, G, Pogarell, O, Kunig, G, Oertel, WH. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13(1): 16–9.CrossRefGoogle ScholarPubMed
41.Piggort, MA, Perry, EK, Marshall, EF, McKeith, IG, Johnson, M, Melrose, HL, Court, JA, Lloyd, S, Fairbairn, A, Brown, A, Thompson, P, Perry, RH. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiar 1998; 44(8): 765–74.CrossRefGoogle Scholar
42.Donnemiller, E, Heilmann, J, Wenning, GK, Berger, W, Decristoforo, C, Moncayo, R, Poewe, W, Ransmayr, G. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 1231-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24(3): 320–5.Google ScholarPubMed